Company intelligence / Profile preview
CanaQuest Medical Corp.
Mississauga, Ontario, Canadacanaquest.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
CQ-001 has shown 35% improvement in efficacy over current treatments for refractory epilepsy in clinical data from the Ontario Brain Institute. The company is pursuing FDA Orphan Drug Status and is in late-stage Phase II trials.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Cannabidiol-based formulationsHempCannabisAlgae oils
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
NRC Canada - Human Health Therapeutics Research Centre
Beyond the preview
Go deeper on CanaQuest Medical Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanaQuest Medical Corp..